Jipyong’s AI, Bio & Healthcare Center provides comprehensive and specialized legal services across highly technical fields such as biotechnology, pharmaceuticals, medical devices, healthcare, and cosmetics. Drawing on extensive hands-on experience and a sophisticated understanding of an industry reshaped by rapid technological change, we deliver practical solutions tailored to each client's needs.
Jipyong recently combined with Jipyong IP, which brings strong technical expertise in the bio and healthcare sectors, and has welcomed leading regulatory specialists covering pharmaceuticals, medical devices, food, and cosmetics. Jipyong IP focuses on the technologies and intellectual property at the heart of these industries, providing integrated, end-to-end counsel from early-stage development through full commercialization. Our long-standing practice experience, now enhanced by deep technical and regulatory expertise, allows us to offer services of significantly greater breadth and depth. To fully integrate this expanded expertise, Jipyong has launched the AI, Bio & Healthcare Center-a center of excellence designed to seamlessly deliver our differentiated services.
The AI, Bio & Healthcare Center supports clients by combining deep industry knowledge, top-tier legal expertise, and a global perspective backed by the largest overseas network of any Korean law firm, with nine offices in eight countries. We have advised life sciences companies of every size on the full spectrum of legal, technical, and business issues-including licensing, compliance matters such as anti-kickback regulation, the design and execution of regulatory approval strategies abroad, and initial public offerings (IPOs) of pharmaceutical companies within Korea’s leading conglomerates. Drawing on its distinctive expertise and know-how, the AI, Bio & Healthcare Center will leverage the deep international capabilities of our Global Risk Management & Strategy Center-spanning international trade, customs, sanctions, export controls, foreign regulation, government affairs, and business strategy-to deliver proactive, multidimensional solutions in a constantly evolving regulatory landscape and support clients at every stage of their business lifecycle.
Many of the Center’s attorneys hold degrees in science and engineering, and its professionals include a medical doctor, a pharmacist, a former Patent Court judge, and patent attorneys, an ideal mix of backgrounds for advising clients across the industry. With its distinctive, global, and deeply experienced practice, the Jipyong AI, Bio & Healthcare Center is committed to being a trusted partner that anticipates and resolves the challenges facing today’s healthcare and life sciences companies.
Key Practice Areas Close
- Supporting compliance guideline and program development covering healthcare regulations, including the Pharmaceutical Affairs Act
- Advisory on matters relating to the Monopoly Regulation and Fair Trade Act, including fair trade practices in the pharmaceutical sector
- Advisory on matters relating to the Medical Service Act and related healthcare administrative regulations
- Advisory on legal issues arising from hospital and clinic operations
- Advisory on matters related to drug pricing systems and National Health Insurance reimbursement pricing adjustments
- Advisory on U.S. Medicare/Medicaid, manufacturer sales and marketing compliance, and fraud and abuse
- Advisory on matters related to patent and license agreements and trade secret protection for bio, pharmaceutical, and medical device companies
- Advisory on patent disputes
- Advisory on product development, technology transfer, and outsourcing transactions
- Advisory on overseas expansion strategies for biotechnology, pharmaceutical, and medical device companies
- Negotiation support and contract advisory for transactions with global companies
- Contract advisory on CRO, CDMO, quality, clinical research, distribution, sales, and consulting agreements
- Matters related to manufacturing, sales, and importation licensing for drugs and medical devices
- Advisory on the distribution, sales, and related operational issues for drugs and medical devices
- Advisory on due diligence, investments, establishing joint ventures, and M&A for biotechnology, pharmaceutical, and healthcare companies
- Advisory on investment and listing for biotechnology, pharmaceutical, and medical device companies
- Advisory on initial public offerings (IPOs) for biotechnology, pharmaceutical, and medical device companies
- Advisory on paid-in capital increase and the issuance of convertible bonds (CBs) and bonds with warrants (BWs) by biotechnology, pharmaceutical, and medical device companies
- Consulting on the establishment of internal control and disclosure frameworks, and management control defense structures for biotechnology, pharmaceutical, and medical device companies
- Advisory on responses to substantive review for delisting of biotechnology, pharmaceutical, and medical device companies
- Advisory on permits and registration procedures for major overseas regulatory bodies (e.g., U.S.’ FDA, Europe’s EMA)
- Advisory on local compliance frameworks (e.g., GDPR, Sunshine Act) and legal risk assessments for global expansion
- Support for responding to investigations and sanctions by overseas regulatory authorities and cross-border dispute resolution
- Review of legal and regulatory issues related to the use of AI technology in the pharmaceutical, healthcare, and medical device sectors
- Legal risk management and advisory on compliance in the adoption and use of AI technology
- Matters related to criminal and administrative litigation in the biotechnology, pharmaceutical, medical device, and healthcare sectors
- Advisory on civil and criminal disputes arising from medical incidents
- Advisory on proactive responses to kickback issues and related fair-trade, tax, and criminal matters
[Regulatory and Compliance Advisory in Healthcare, Biotechnology, Pharmaceutical, and Medical Device Industries]
[Intellectual Property]
[Licensing, Collaboration, Partnerships, JVs]
[Contracts in the Biotechnology, Pharmaceutical, and Medical Device Industries]
[M&A and Investment]
[IPOs and Capital Markets]
[Global Expansion and Foreign Regulatory Compliance]
[AI-driven Pharmaceutical and Healthcare Innovation]
[Litigation and Arbitration]
Experience Close
- Advised Company L on compliance by its Vietnamese subsidiary
- Advised Company I, a pharmaceutical company, on the regulations under the Fair Trade Act
- Advised Company S, a biopharmaceutical company, on its FCPA compliance
- Represented Company C and Company D, both pharmaceutical companies, in a case involving kickback payments
- Advised Company G, a global medical device company, on sales/marketing compliance program
- Advised on legal issues relating to the enhancement and development of healthcare services
- Advised Korea Drug Development Fund on drug development program support and national R&D project management
- Advised Company D, a pharmaceutical company, on its response strategies for drug side effects and the permissible scope of rebates
- Advised on matters involving the Ministry of Food and Drug Safety and the Ministry of Health and Welfare
- Advised Merck on legal remedies against threats to sound pharmaceutical transactions, including illegal product sales and trademark infringement
- Advised Company R on legal issues related to stem cell technologies, establishment of foundation, and technology leakage
- Advised pharmaceutical companies on trademark matters, patent and licensing agreements, and protection of trade secrets against unfair competition
- Advised Company S on licensing matters for the manufacturing, sale and importation of its medical devices
- Advised Company D, a pharmaceutical company, on trademark infringement issues relating to its contrast media product
- Advised Company B, a medical device company, on a trade secret infringement claim
- Advised on the review and negotiation of a license agreement for Cenobamate products
- Advised GC Cell on a license agreement with Rivaara Immune, an Indian cell therapy development company
- Advised Curacle Co., Ltd. on the negotiation and execution of a license agreement
- Advised PharmAbcine Inc. on a license agreement with its U.S. subsidiary, Wincal Biopharm
- Advised Company B, a biopharmaceutical company, on the transfer of anticancer drug technology from a leading global research institute, joint R&D, and the establishment of a joint venture
- Advised Company S, a diagnostics company, on collaboration and partnership transactions, including strategic alliances, joint R&D, product development and technology transfer, with multinational diagnostics and biotech companies
- Advised Medicinal Bioconvergence Research Center on license agreements and joint R&D agreement(s) relating to drug targets
- Advised Company M on the establishment of a joint venture in Singapore and a medical corporation in Vietnam
- Advised Company B on the establishment of a joint venture in China
- Advised Hospital S on its expansion into Iran and Russia
- Advised multiple medical foundations, including Medical Foundation A, on their compliance with the Medical Service Act and overseas expansion
- Advised Deargen Inc., an AI-based drug discovery platform company, on the negotiation and execution of a joint research agreement with SK Chemicals on drug repurposing and new drug development
- Advised Deargen Inc. on the negotiation and execution of an AI-based liver cancer vaccine development agreement with Optipharm, Inc.
- Advised PharmAbcine Inc. on the negotiation and execution of a research agreement with the U.S. National Institutes of Health (NIH) on therapeutic candidates for pathological neovascularization
- Advised Seegene Inc. on a supply agreement for COVID-19 diagnostic kits with the City of Los Angeles
- Advised Company C, Company B, and Company I, all medical device companies, on general contractual matters
- Advised Company R, a NASDAQ-listed pharmaceutical company, on the negotiation of various contracts relating to clinical trials, product development, and manufacturing
- Advised Company G on the negotiation of contracts relating to biopharmaceutical drug development
- Advised Nurron Pharmaceuticals, a U.S.-based drug discovery company, on securing investment from Daewoong Pharmaceutical Co., Ltd. and HanAll Biopharma Co., Ltd. for the development of Parkinson's disease treatments
- Advised Deargen Inc., an AI-based drug discovery platform company, on the sale of its shares and controlling interest to Amyloid Solution, a biotech venture
- Advised on the merger of Genexine and Toolgen
- Advised on the acquisition of a contrast media manufacturing plant from Bayer
- Advised Easy Bio Inc. on its acquisition of shares in Pathway Intermediates Inc., a U.K.-based biotechnology company
- Advised LegoChem Biosciences, Inc. on its merger with KHANMED Co., Ltd., a pharmaceutical distributor
- Advised Shinhan Investment Corp. on its investment in Genexine
- Advised SK Biopharmaceuticals on its IPO on the KOSPI Market
- Advised Samsung Securities and Prestige Biopharma on Prestige Biopharma's KOSPI listing
- Advised Korea Investment & Securities and Proteina on a KOSDAQ market listing
- Advised Mirae Asset Securities and Neurophet on a KOSDAQ market listing
- Advised Mirae Asset Securities and IMBDx on a KOSDAQ market listing
- Advised Samsung Securities and HASS on a KOSDAQ market listing
- Advised Korea Investment & Securities and NEXTBiomedical on a KOSDAQ market listing.
- Advised Mirae Asset Securities and ONCOCROSS on a KOSDAQ market listing
- Advised Mirae Asset Securities and S.BIOMEDICS on a KOSDAQ market listing
- Advised Y-Biologics on its listing on a KOSDAQ market listing
- Advised Mirae Asset Securities and PlasmApp on a KOSDAQ market listing
- Advised Korea Investment & Securities and Noul on a KOSDAQ market listing
- Advised Mirae Asset Securities and ABION on a KOSDAQ market listing
- Advised BioPlus on a KOSDAQ market listing.
- Advised Mirae Asset Daewoo and Prestige Biologics on a KOSDAQ market listing.
- Advised Samsung Securities and GeneSystem on a KOSDAQ market listing
- Advised Mirae Asset Daewoo on a KOSDAQ market listing of Gencurix, a cancer-focused molecular diagnostics company
- Advised Mirae Asset Daewoo on ilooda's KOSDAQ market listing
- Advised Mirae Asset Daewoo on Korea Pharma's KOSDAQ market listing
- Advised Mirae Asset Daewoo and P&K Skin Research Center on a KOSDAQ market listing.
- Advised Aptamer Sciences and Kiwoom Securities on a KOSDAQ market listing
- Advised Korea Investment & Securities and T&L on a KOSDAQ market listing
- Advised Samsung Securities on NFC's KOSDAQ market listing
- Advised Korea Investment & Securities on ENBIO's KOSDAQ market listing
- Advised NGeneBio on its KOSDAQ market listing
- Advised Korea Investment & Securities and Precision Bio on a KOSDAQ market listing
- Advised Kiwoom Securities and T&R Biofab on a KOSDAQ market listing
- Advised Kiwoom Securities and CytoGen on a KOSDAQ market listing
- Advised Korea Investment & Securities and BIFIDO on a KOSDAQ market listing
- Advised Mirae Asset Daewoo and Newtree on a KOSDAQ market listing
- Advised Kiwoom Securities and Icure Pharmaceutical on a KOSDAQ market listing
- Advised Genofocus on its KOSDAQ market listing
- Advised GC MS on its KOSDAQ market listing
- Advised Nanogen, the largest biosimilar company in Vietnam, on its listing on the Korea Exchange (KRX)
- Advised Prestige Biopharma, a Singapore-based biosimilar company, on its listing on the Korea Exchange (KRX)
- Advised NeoImmuneTech, a U.S.-based company, on the establishment of its disclosure system and maintenance of its listing status
- Successfully represented the Director of the Busan Regional Office of Food and Drug Safety before the Supreme Court, securing a reverse-and-remand decision in a case concerning a corrective order for krill oil products
- Represented the Director of the Seoul Regional Office of Food and Drug Safety and prevailed on appeal in a lawsuit seeking revocation of a non-conformity ruling for under-content probiotic products, as well as in a related lawsuit seeking revocation of an administrative fine
- Represented the Director of the Daegu Regional Office of Food and Drug Safety and prevailed on appeal in a lawsuit seeking revocation of an advertising suspension order regarding moisturizing lotion advertisements
- Advised Company C and Company D, pharmaceutical companies, on criminal and tax matters relating to alleged kickback arrangements
- Advised Company S, a pharmaceutical company, on response strategies for a clinical drug administration incident
- Advised on civil and criminal disputes arising from medical incidents, including expert analysis of medical records
- Represented a client before the Supreme Court in a case concerning required measures in the transfer of emergency patients
- Represented a client in a constitutional complaint (seeking revocation of a no-indictment disposition) regarding the duty to maintain a patent airway
[Regulatory Requirements and Compliance]
[Intellectual Property]
[Licensing, Collaboration, Partnerships and JVs]
[Contracts in the Biotechnology, Pharmaceutical and Medical Device Industries]
[M&A and Investment]
[IPOs and Capital Markets]
[Litigation and Arbitration]
